Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6,400 Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
Early Cancer Detection
Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
N/A N=204 The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
N/A N=3,051 S1204, Viral Screening in Newly Diagnosed Cancer Patients
Cancer
Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
N/A N=30 Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001
N/A N=105 Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Phase 2 N=128 Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…
N/A N=89 Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion
Breast Carcinoma · Invasive Breast Carcinoma
Primary: Accuracy of CEM for Incremental Cancer Detection in the Ipsilateral and Contralateral Breasts. — 41.4 % of malignancy in new CEM lesions
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=2,000 Primary Diagnosis Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System
Pathology
Primary: Major Discordance Rate — 3.5; 3.1 Percentage of Major Discordances
Phase 2 N=40 Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
Prostate Cancer
Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
N/A N=79 Empowering Patients' Lung Cancer Screening Uptake
Lung Cancer
Primary: Order of LDCT — 50 Participants
N/A N=50 Esophageal Cytology With FISH in Detecting Esophageal Cancer
Dysphagia · Dysplasia · Esophageal Adenocarcinoma
Primary: Sensitivity of Sponge Cytology Using FISH — 13.3 percentage of cases among positive tests
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
N/A N=23 App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
Cancer
Primary: Interviews — 20 Interviews
N/A N=15 PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIA Colon Cancer
Primary: Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the…
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
N/A N=2,074 Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
Neoplasm
Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Phase 3 N=11 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed